Product Description
Ondansetron is one of the medications most commonly used for empiric treatment of nausea and vomiting. Ondansetron has extreme utility as an antiemetic drug, and it is effective against nausea and vomiting of various etiologies. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29763014/)
Mechanisms of Action: 5-HT3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, China, France, Italy, Poland, Spain, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Pain|Cervical Cancer|Endometrial Cancer|Fallopian Tube Cancer|Morphine Dependence|Ovarian Cancer|Pain, Postoperative|Uterine Cancer
Phase 2: Alzheimer Disease|Other|Peritoneal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2022-502983-19-00 |
ZNâc3-005 | P2 |
Recruiting |
Fallopian Tube Cancer|Peritoneal Cancer|Ovarian Cancer |
2027-09-01 |
2025-05-02 |
Treatments |
|
2024-518523-30-00 |
ADVANCE-AD04-001 | P2 |
Recruiting |
Alzheimer Disease |
2026-12-31 |
2025-05-02 |
Treatments |
|
NCT06007586 |
CINV202306 | P3 |
Completed |
Ovarian Cancer|Endometrial Cancer|Uterine Cancer|Cervical Cancer|Fallopian Tube Cancer |
2025-06-20 |
6% |
2025-12-05 |
Primary Endpoints|Treatments |
NCT04606264 |
STUDY19030022 | P3 |
Completed |
Acute Pain|Morphine Dependence|Pain, Postoperative |
2025-03-21 |
2025-10-23 |
||
CTR20170613 |
CTR20170613 | P2 |
Recruiting |
Other |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |